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tion of all direct costs we determined that the total average cost of uncomplicated 
hypothyroidism during pregnancy and childbed per women was € 124.79. In the 
cost structure of health care provision for pregnant women with uncomplicated 
hypothyroidism the most significant costs are spent on thyroid laboratory tests.
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Objectives: Diabetes is a major economic burden disease globally. The geriatric 
diabetic cost economic studies in India are limited. Hence this study carried out 
with the objective to assess the various costs incurred during the geriatric dia-
betic treatment (COI model). MethOds: This was a prospective, cross sectional 
study conducted from July 2012-July 2014 in the General Medicine Department of 
Kasturba Medical College Hospital, Manipal, after obtaining ethical clearance. Cost 
details were obtained from hospital finance and pharmacy. The Descriptive sta-
tistical method was applied Results: A total of 475 cases were enrolled of which 
52.42% had diabetes. Of this, 27.71% had DM alone, 6.82 % had DM associated renal 
disease (i.e.: 3.6% were DMAKI, 3.2% were DMCKD), 12.44% had other than renal 
DM complications (microvascular), 48.19% had both DMHTN, 4.81% had DMHTN 
associated complications. The total cost incurred for the treatment of the disease 
and its related complications (DM alone, DMAKD, DMCKD, DM neurological compli-
cations, DMHTN & DMHTN) did not vary significantly [ I.e. Mean+ SD (INR): 16044.7 
+ 37740.06, 15374.51+ 11915.94, 14840.03+14124.05, 8395.35+ 16580.11, 27130.28 + 
64934.04, 14430.5+ 13113.78 ) . The cost of treatment (INR) appeared low due to vary-
ing factors like free screening or treatment for other symptoms, etc. The cost based 
on various factors were as listed - Medicine charge > Laboratory/diagnostic charges 
> Nursing charges > Material charges > Procedure charges > Professional charges 
> Admission related charges > Miscellaneous charges. cOnclusiOns: This study 
clearly suggests that medicine expense is the highest cost factor in DM treatment. 
The second highest cost was laboratory followed by nursing costs. Research on 
pharmacoeconomic models like cost effective analysis (CEA), Cost minimization 
analysis (CMA), and Cost benefit analysis (CBA) by the pharmacist &the stakehold-
ers is essential to reduce the burden in geriatrics. Lack of availability of direct non-
medical cost was the limitation of this study
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Objectives: as a result of type II Diabetes Mellitus (T2DM), patient may develop sev-
eral complications, which cause serious economic burden to health care system. The 
objective of the study was to evaluate the treatment cost of T2DM in Estonia for 4 
serious complications: myocardial infarction (MI), stroke, nephropathy and retinopa-
thy during the year, when the event developed and a year later. MethOds: anony-
mous data about T2DM patients´ treatment records was obtained from Estonian 
Health Insurance Fund for the years 2001-2011. The complications were defined 
by ICD-10 codes and following criteria were applied for the sample to be analysed: 
the complication had been detected first time between the years 2004-2008 (no 
complication during the preceding 3 years). The data did not include outpatient 
medication consumption. The control group consisted of randomly chosen T2DM 
patients, who did not have the complication during this time period. Data analy-
sis was performed using Stata 11. Results: the overall sample consisted of 3016 
patients (age 45-69). Inpatient and outpatient treatment costs were calculated for 
MI, stroke, nephropathy and retinopathy for the year, when the event occurred, and 
for the year later. The highest treatment costs appeared during the year, when the 
event was recorded, and were for the MI 6,844, stroke 4,113, nephropathy 3,473 and 
retinopathy 598 EUR. A year later the costs were 1,860 (-73%), 2824 (-32%), 2490 (-29%) 
and 701 (+17) accordingly. cOnclusiOns: MI and stroke are amongst highest costs 
during the first year and a year later the costs are lower, however for retinopathy 
the cost is higher than the first year. A year later, cost of stroke remains higher than 
MI, presumably due to follow-up care. The complication cost data obtained gives 
information about the healthcare expenditure in Estonia and can be used for cost-
effectiveness assessment for new diabetes medications.
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Objectives: The number of patients in the Czech Republic treated for diabetes in 
2013 was nearly 862 thousand. The Type 2 diabetes mellitus share was 91.7 %. The 
number of treated diabetics has been increasing in a long-term trend as well as 
the number of their chronic complications. The goal of the study is to estimate the 
cost of type 2 diabetes from the health insurance perspective in a newly established 
regional diabetology outpatient facility. MethOds: The cost-of-illness analysis of 
the direct costs was performed from the third-party payer perspective based on 
data from the year 2014. The bottom-up approach was used. Data of all 552 patients 
with Type 2 diabetes were (all patients with Type 2 Diabetes in the ambulance) 
were taken into consideration. Altogether 1 696 consultations were provided to the 
patients during the particular year. Results: The average cost of consultations for 
one type-2-diabetes patient per year was CZK 840.56 (~EUR 30.5), the average cost 
of treatment for one patient was CZK 10 336 (~EUR 375), the average material cost 
was CZK 2 835 (~EUR 103) per patient, and CZK 113.7 (~EUR 4) was the average cost 
for amputation per patient, and the average cost of diabetic nephropathy was CZK 
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Objectives: The aim of this study was to assess the indirect costs associated 
with types 1 diabetes mellitus (DM) from the perspective of the Social Insurance 
Institution (ZUS) in Poland. MethOds: The estimates were based on data from 
the year 2013 concerning absence from work due to the illness (sick leave) the 
amount of short-term disability, the sufferers of which claim rehabilitation ben-
efit, and the amount of permanent (or long-term) disability, the sufferers of which 
claim disability pension. Cost analysis was performed based on the Human Capital 
Approach taking into account Gross Domestic Product (GDP) per capita equaled 10 
278 EUR. Results: Total indirect costs of DM types 1 in the year 2013 in Poland 
were 80 148 008 EUR. Total indirect costs associated with absenteeism were 8 263 
EUR calculated using GDP per capita per patient. The highest component of indirect 
costs of DM type 1 was long-term disability, in particular unlimited period, which 
accounted for 71%. Long-term (limited period), short term disability and sick leave 
costs constitute 17%, 3% and 9% of total indirect costs of DM type 1, respectively. 
One sick leave of a person with types 1 diabetes generated a cost of lost productiv-
ity equal to 431 EUR. The cost of disability pension per one person was higher than 
rehabilitation benefit, and equalled 20 600 EUR (limited period) and 362 505 EUR 
(unlimited period) compared with 3 611 EUR. cOnclusiOns: DM in Poland gener-
ated high indirect costs. The main component was long-term disability, in particular 
unlimited period; rehabilitation benefit and disability pension (limited period) and 
sick leave generated much lower costs for Social Insurance Institution.
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Objectives: This is the first study that assesses the economic costs of Type 1 
Diabetes Mellitus (T1DM) in pediatric patients in Spain. The main objective of this 
study was to estimate direct healthcare costs (DHC) and direct non-healthcare costs 
(DNHC) of T1DM in children and adolescents. MethOds: CHRYSTAL (Costs and 
Health Related qualitY of life Study for Type 1 diAbetes meLlitus pediatric patients 
in Spain) is an observational study conducted in 2014 on a representative sample of 
275 patients aged 1-17 years diagnosed with T1DM, distributed across 12 hospitals 
in Spain. The study followed a bottom-up-approach to costing from a societal per-
spective. Data on demographic and clinical characteristics, health resource utiliza-
tion, and informal care were collected cross-sectionally from medical records and 
questionnaires completed by clinicians and patients´ caregivers. The reference year 
for unit prices was 2014. Results: The average annual cost for a T1DM patient was 
€ 27,349. DHC amounted to € 4,144, with statistically significant differences depend-
ing on glycemic control (HbA1c < 7.5% versus HbA1c ≥ 7.5%): € 3,683 versus € 4,788 
(p< 0.05) and the existence of patient with acute and chronic complications (except 
hypoglycemia) and related comorbidities (with versus without): € 5,777 versus € 3,713 
(p< 0.05) after controlling for age and gender. The largest DHC were diabetes supplies 
(€ 2,035), outpatient visits (€ 841), and medication (€ 670). Average DNHC were € 23,204. 
Informal care (the time that caregivers spend in T1DM related caregiving tasks) 
represented 97.5% of DNHC (€ 22,618) and 82.7% of total costs. cOnclusiOns: T1DM 
in children and adolescent patients carries a considerable social economic burden, 
especially in terms of informal care, which accounts for the largest proportion of 
total costs associated to the disease. The results shed light on the allocation of 
T1DM related resources, and might enlighten T1DM policy priority setting in Spain.
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bAckgROund: Hypothyroidism is a common disease during pregnancy with 
important medical and social significance. However, there is no real study eval-
uating the economic analysis of this pathology during pregnancy and childbed 
in Czech Republic. Objectives: To determine the real medical cost associated 
with uncomplicated hypothyroidism during pregnancy and childbed in Czech 
Republic. MethOds: The 10 years retrospective non-randomized cross-sectional 
study was performed in 172 pregnant women with hypothyroidism with uncom-
plicated disease course who were followed and examined according to the rec-
ommendation of the guidelines of American Thyroid Association. The study was 
performed in the settings of Departments of Endocrinology of a university hospital 
and with laboratory assessment in a single center. We assessed serum concentra-
tions of thyroid hormones and finally, we calculated the cost of illness to estimate 
the cost of health care for uncomplicated hypothyroidism during pregnancy and 
childbed. Results: Of the 172 positively screened women in the first trimester, 112 
(65.12%) had subclinical hypothyroidism and 40 (34.88%) had overt hypothyroidism. 
Seventy (40.7%) had already been treated for hypothyroidism before inclusion in 
the study and 102 (59.3%) were newly diagnosed. The median dose of levothyroxine 
was 58.83ug/day (range: 0-174) and median frequency of laboratory and medical 
check-up was 4.5 (range 3-6). The total average annual cost of laboratory tests was 
€ 852.91, the cost of entrance endocrine examination € 229.02, follow-up endocrine 
examination € 364.92 and levothyroxine therapy € 105.65. The total average cost of 
first medical and laboratory check-up during pregnancy per women was € 34.67 and 
of one follow-up examination € 17.67 per women. cOnclusiOns: After calcula-
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Type 2 diabetes or non-diabetic patients (50.3 years, vs. 69.5 and 66.6 years respec-
tively) at the time of surgery. The average cost of diabetic patients (both types) was 
more than twice the cost of non-diabetics in both glaucoma surgery (€ 7,972 vs. 
€ 3,278; p< 0.001) and cataract extractions (€ 10,668 vs. € 3,935; p= 0.031) and about 
30% higher in vitrectomies (€ 3,755 vs. € 2,869; p< 0.001). LOS was also systematically 
higher in diabetic patients (glaucoma surgery: 5.8 vs. 2.4 days; vitrectomy: 2.3 vs. 1.7 
days; cataract extraction: 14.7 vs. 3.0 days). cOnclusiOns: The presence of diabetes 
increases dramatically both LOS and hospitalization costs in patients undergoing 
ophthalmological surgery.
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Objectives: To estimate annual productivity loss costs attributable to having obe-
sity in working US adults with diabetes. MethOds: This study applied a cross-
sectional design using the 2003-2012 Medical Expenditure Panel Survey (MEPS) data. 
Asthma patients (18-64 years old) were self-reported, had a Clinical Classification 
Codes of 0049, 050, or ICD-9-CM code of 250. To investigate the impact of having 
obesity, patients were classified as normal-weight (18.5≤ BMI< 25), overweight (25≤ 
BMI< 30), and obese (BMI≥ 30). Productivity loss costs, which were measured based 
on missed work days due to illness or injury for one year and the hourly wage, were 
estimated using a two-part model to adjust for patients with zero costs. To estimate 
the productivity loss costs attributable to having obesity, each group of costs was 
estimated by assuming everybody to be obese; these costs were then re-estimated by 
assuming everybody was normal weight, and the mean difference between the two 
estimated costs was calculated. All costs were converted to 2013 US dollars using 
the Consumer Price Index. Results: Among a total of 6,992 working adults with 
diabetes, the prevalence of normal-weight was 12.9%, overweight 30.1%, and obese 
57.0%. Annual average productivity loss costs for normal-weight and obesity in dia-
betes patients were $471(95%CI:$354-$588) and $585(95%CI:$523-$647) per patient, 
respectively. Among patients with diabetes who had loss of productivity costs, those 
with obesity had 1.02 times greater productivity loss costs than normal-weight 
patients after adjusting for patients’ demographic and clinical characteristics. The 
adjusted productivity loss costs attributable to having obesity in working diabetes 
patients was estimated at $77(95%CI:$76-$78) per patient per year. cOnclusiOns: 
The loss of productivity costs among US diabetes patients is substantial, which is 
amplified by the presence of obesity. This study highlights the importance of obesity 
control in order to reduce costs and enhance productivity in patients with diabetes.
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Objectives: Changes in healthcare resource utilization by Type 2 diabetes (T2D) 
patients over time are important for understanding the effects that treatment 
paradigms may have on costs of disease. This study was a longitudinal assessment 
of real-world claims data which followed changes in treatment costs for a single 
cohort (N= 35017) of newly diagnosed T2D patients. MethOds: The Truven Health 
MarketScan® Database was examined for claims data from US-based T2D patients. 
Inclusion criteria were: at least 2 diagnoses according to ICD-9 codes for T2D, or 1 
T2D diagnosis plus 1 or more OAD claims, and allowing 1 possible misdiagnosis for 
type 1 diabetes, ≥ 18 years of age, continuous enrolment starting from 2006 (index 
year) to 2012 in a plan with prescription benefits, and at least 1 prescription for any 
anti-diabetic drug . All-cause costs of inpatient and outpatient services, medications, 
and supplies were analyzed. Results: From 2006-2012, total annual costs/patient 
increased from $9,817 to $12,551, adjusted to 2012 levels. Costs for outpatient ser-
vices grew 33% ($4,214-$5,645/outpatient). Outpatient emergency room utilizer costs 
rose 40% ($1,846-$2,586/utilizer). Total inpatient costs rose 47% ($19,453-$28,526), 
followed by a 36% growth of inpatient emergency room costs ($15,823-$21,526). 
Inpatient costs/1-day stay rose from $3,473 to $4,322, and inpatient ER costs/1-day 
stay increased from $2,776-$3,261. From 2006-2012, mean total days/stay/inpatient 
remained stable between 5.6 to 6.0 days, indicating annually increasing costs for 
inpatient services. Overall annual drug costs/utilizer increased 14% ($2,969-$3,389), 
as did anti-diabetic drug costs/utilizer (81%; $474-$858). Between 2006-2012, diag-
nosed T2D-assocated comorbidities increased as follows: cerebrovascular disease 
(13%-21%), peripheral vascular (3%-10%), nephropathy (3%-13%), and retinopathy 
(4%-14%). cOnclusiOns: Costs for all types of resource utilization increased, rang-
ing from 17% to 81%, mainly driven by increased inpatient costs. Population aging 
may partly be responsible for the increased comorbidities, thus accounting for some 
increased treatment costs, along with increased drug costs.
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Objectives: The SGLT2 inhibitor dapagliflozin (DAPA) increases glucosuria in an 
insulin-independent manner resulting in reductions in hyperglycemia, weight 
and BP with a low risk of hypoglycemia. Glipizide (GLIP) reduces hyperglycemia by 
increasing beta cell insulin secretion with risk of hypoglycaemia and weight gain. 
We conducted a cost analysis of treating patients over 4 years to two relevant com-
posite endpoints: (1) HbA1c lowering of ≤ 0.5%, no major or minor hypoglycaemic 
events and weight loss ≥ 3% and (2) HbA1c lowering of ≤ 0.5%, no major or minor 
hypoglycaemic events and weight loss ≥ 5%. MethOds: The Cardiff Diabetes model 
41 841 (~EUR 1 518) per one patient. The total average cost per one type-2-diabetes 
patient was CZK 55 956 (~EUR 2.031) in 2014. cOnclusiOns: Our data indicate that 
the cost of type 2 diabetes mellitus was CZK 55 956 (~EUR 2 031). A longitudinal study 
is, however, required to confirm the development of the average patient cost and 
take account of the cost of complications.
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Objectives: diabetic foot syndrome (DFS) is expensive complication of diabetes 
leading to disability. There are costly innovative drugs that can make complications 
more curable. It is necessary to obtain evidences of new technologies economic ben-
efits. The aim of the study was to determine the economic burden of DFS in health 
care of the Republic of Belarus. MethOds: “cost of illness” analysis for outpatient 
and inpatient treatment of DFS patients has been performed. A retrospective study 
of treatment of 15 outpatients with diabetic ulcers and 16 inpatients who under-
went amputation of different levels has been made. Direct and indirect costs were 
estimated. Average, minimal, maximal costs were calculated. All costs are given in 
euros (may, 2015). Results: out-patient direct medical costs are 259 (78 to 636) per 
patient/year. Indirect costs are 1941 (from 1022 to 4357) per patient/year. The cost 
of “big” amputation is 5248 (from 647 to 13,556) per hospitalization and 1099 (from 
282 to 3702 euros) for “small” amputations. Indirect costs range from 352 to 978 
during the period of treatment. cOnclusiOns: Amputation usually considered 
as emergency aid in the case of DFS makes significant financial burden for hospi-
tals and health care system. Careful assesment of cost of illness of diabetes and 
it’s complications allows to expand opportunities of expansive outpatient medical 
technologies use.
PDB39
cost of tyPe 2 DiaBetes accorDinG to Glucose-lowerinG meDications 
in france
Charbonnel B1, Dallongeville J2, Simon D3, Bureau I4, Leproust S5, Levy-Bachelot L5, 
Gourmelen J6, Detournay B7
1University of Nantes, Nantes, France, 2Pasteur Institute, Lille, France, 3Pitie Hospital, Paris, 
France, 4Cemka-Eval, Bourg la Reine, France, 5MSD France, COURBEVOIE, France, 6UMS 011 - 
Inserm - UVSQ, Villejuif, France, 7Cemka-Eval, Bourg-la-Reine, France
Objectives: With the introduction and delisting of some glucose-lowering medi-
cations, pharmacological treatments in T2D have changed in the recent years and 
details of the current drug use patterns are not known. This descriptive study 
aims to describe characteristics of patients with type 2 diabetes and patterns of 
use of antihyperglycemic agents in France in 2013. MethOds: A random sample 
of ≈ 600,000 patients registered in the French national health insurances reim-
bursement database was used. Patients with diabetes were identified through 
their use of glucose-lowering medication and coding of hospital stays and long-
standing condition insurance coverage in the database. Drug utilization pattern 
of antihyperglycemic agents were estimated considering prescriptions in Q4 2013 
and compared to data from Q4 2007. Results: Overall 28,708 patients with T2D 
(estimated database prevalence 4.5%, 8.8% in people aged 40 and over) were iden-
tified in 2013. Mean age was 67.5 (SD 12.9), 54.1% were male. In Q4, 41.2% of T2D 
pharmacologically treated patients received a monotherapy, 25.6% a dual therapy, 
13.7% a multi-therapy and 19.5% an insulin therapy with or without other hypo-
glycemic agents. Compared to 2007 data, a slight but significant increasing trend 
toward combination therapies and insulin was observed. The use of metformin 
increased over time especially in monotherapy (66% among monotherapy in 2013 
versus 50% in 2007). All thiazolidinediones and some sulfonylureas treatments 
were replaced by DPP-4 inhibitors and to a much lesser extent with GLP-1 ana-
logues. cOnclusiOns: Antihyperglycemic prescription patterns in France have 
changed in recent years in parallel with the introduction of different classes 
of medications to the marketplace but probably also in an attempt to improve 
glycemic control of patients. Knowledge of real life pattern of drug utilization 
remains an important dimension to better understand therapeutic needs in T2D 
management.
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Objectives: Ophthalmological complications (glaucoma, retinopathy, cataract) are 
frequent in patients with type I or type II diabetes and often require surgical treat-
ment. This study aimed at assessing the impact of diabetes on the hospitalization 
costs and the length of stay associated with these surgical treatments in Belgium, 
using retrospective data. MethOds: The average hospitalization cost and the aver-
age length of stay (LOS) among patients hospitalized for ophthalmological surgery 
were estimated using the longitudinal IMS Hospital Disease Database (year 2013), 
including data (diagnoses, procedures, costs) on 24% of Belgian hospital beds. Stays 
were searched based on ICD-9-CM procedure codes corresponding to surgery for 
glaucoma (12.1 to 12.7), vitrectomy (14.71-14.74) and cataract extraction (13.19, 13.6). 
Patients were identified as diabetic if at least one diagnostic of diabetes (ICD-9-CM: 
249-250) had been documented during the calendar year. The impact of diabetes on 
LOS/ cost was assessed through Wilcoxon non-parametrical tests. Results: 671 
stays with surgery for glaucoma, 1,438 stays with vitrectomy and 204 stays with 
cataract extraction were retrieved in the database (with diabetic patients accounting 
for 56, 202 and 24 of these stays respectively). Patients with Type I diabetes (n= 16, 
split between glaucoma surgery and vitrectomy) were significantly younger than 
